患者管理方法:≥50岁低血清睾酮浓度男性的评估与治疗
本文针对≥50岁、体重指数>25 kg/m2且合并多种共病的男性,讨论其雄激素缺乏临床特征与低血清睾酮浓度时的评估与治疗。因缺乏大型长期睾酮治疗试验评估确定性临床终点,是否启动睾酮治疗需在有限证据下进行获益-风险分析。作者通过病例场景提出实用临床评估与管理路径。
要点
- ≥50岁男性若体重指数>25 kg/m2且合并多种共病,常出现雄激素缺乏临床特征和低血清睾酮浓度。
- 因缺乏大型长期睾酮治疗试验评估确定性临床终点,年龄相关睾酮下降者是否治疗尚不明确。
- 临床医生面临是否启动睾酮治疗的难题,需在有限临床试验证据下进行获益-风险分析。
核心结论
- 对于因下丘脑-垂体-睾丸轴明确病变导致经典性腺功能减退的男性,睾酮替代治疗无争议;但对于年龄相关循环睾酮下降的男性,睾酮治疗的作用尚不明确。
研究设计与样本
- 本文为采用病例场景的临床实践方法论述,未报告系统检索范围或样本量。
主要发现
- ≥50岁男性,尤其体重指数>25 kg/m2且合并多种共病者,常表现为雄激素缺乏临床特征和低血清睾酮浓度。
- 缺乏大型长期睾酮治疗试验评估确定性临床终点,是年龄相关睾酮下降者治疗作用不明确的原因。
临床怎么用
- 临床医生面对此类男性需决定是否启动睾酮治疗,应在有限临床试验证据下进行获益-风险分析。
局限性
- 原文指出缺乏大型、长期睾酮治疗试验评估确定性临床终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although testosterone replacement in men with classic hypogonadism due to an identified pathology of the hypothalamic-pituitary-testicular axis is uncontroversial, the role of testosterone treatment for men with age-related declines in circulating testosterone is unclear. This is due to the lack of large, long-term testosterone therapy trials assessing definitive clinical endpoints. However, men ≥50 years of age, particularly those who have a body mass index >25 kg/m2 and multiple comorbidities, commonly present with clinical features of androgen deficiency and low serum testosterone concentrations. Clinicians are faced with the question whether to initiate testosterone therapy, a difficult dilemma that entails a benefit-risk analysis with limited evidence from clinical trials. Using a case scenario, we present a practical approach to the clinical assessment and management of such men.
引用
- Grossmann M, Jayasena CN, Anawalt BD, et al. Approach to the Patient: The Evaluation and Management of Men ≥50 Years With Low Serum Testosterone Concentration. J Clin Endocrinol Metab. 2023. PMID: 36995891. doi:10.1210/clinem/dgad180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。